Helus Pharma Faces a Crucial Test: Can Clinical Data Outweigh Political Tailwinds?

Even an executive order from the White House hasn’t been enough to stop the bleeding. Shares of Helus Pharma, the psychedelic therapy developer formerly known as Cybin, have shed more than 53% of their value over the past twelve months, with the stock trading at just $3.86 — barely above its 52-week low of an undisclosed trough, and a long way from the high of $9.83. The daily slide of 3.74% on the latest session underlines a market that is tuning out the political noise and demanding hard evidence.

The company now carries a market capitalisation of approximately €186 million. Technical indicators paint a picture of extreme stress: the relative strength index (RSI) has sunk to 30, a level that typically signals oversold conditions, while the annualised 30-day volatility stands at a staggering 131%, reflecting deep investor jitters. In the biotech world, however, a low RSI is no guarantee of a rebound — shares can languish for long stretches without a powerful catalyst.

That catalyst, for now, is purely clinical. The political environment has undoubtedly improved. In April, the White House issued an executive order designed to accelerate research, regulatory pathways and patient access for psychedelic therapies. The directive calls for prioritised FDA review of drugs with Breakthrough Therapy designation — a status that Helus already holds for its lead candidate, HLP003, in major depressive disorder — as well as expanded federal funding and tighter coordination with the Department of Veterans Affairs. The FDA has signalled its support, urging a faster pace for studies while insisting that decisions must rest on rigorous scientific data.

Helus welcomed the executive order, but management has been careful to frame the sector’s future as dependent on clinical evidence, not political momentum. The market seems to agree, punishing the stock even as the regulatory backdrop brightens. The message is blunt: a favourable policy climate alone cannot compensate for missing top-line results.

Should investors sell immediately? Or is it worth buying Cybin (Helus Pharma)?

Adding to investor uncertainty was the abrupt departure of chief executive Michael Cola in April, at the board’s request. Co-founder and executive chairman Eric So stepped in as interim CEO while a permanent successor is sought. For a clinical-stage biotech approaching a make-or-break data point, that governance shake-up is no minor detail. So has framed his return as a continuity play, stressing that the APPROACH study for HLP003 remains the top priority. Analysts see the company as a “delivery bet” — not a turnaround story or a pure science wager, but an execution wager with an unresolved leadership question on top.

That bet hinges squarely on HLP003. The late-stage trial in severe depression, backed by the FDA’s Breakthrough Therapy designation, is expected to yield its primary readout in the fourth quarter of 2026. The outcome is binary: positive data could unlock commercial potential; failure would leave the stock stranded regardless of any political tailwind.

Helus does have a second string to its bow. In March, the company reported positive top-line results from a Phase 2 signal-detection study of HLP004 for generalised anxiety disorder, tested as an add-on therapy in patients who remained symptomatic despite standard antidepressant treatment. That data broadens the pipeline narrative, but it should not distract from the central importance of HLP003. The near-to-medium-term story of the stock rests on whether the APPROACH study delivers.

Encouragingly, management has taken steps to address one of the less glamorous but most critical challenges in psychiatric drug development: patient recruitment. In April, Helus announced a partnership with TARA Mind to target veteran communities for enrolment in the PARADIGM-HLP003 programme. The collaboration aligns with the broader push from the White House and the VA to improve access for veterans, a population that regulators and clinicians take seriously. While the tie-up neither guarantees recruitment success nor validates the drug’s efficacy, it signals that the company is focusing on the practical, execution-heavy part of the pipeline.

Despite these moves, the stock remains under heavy pressure. The rebranding from Cybin to Helus Pharma was meant to shed the speculative “psychedelics” label and project a more serious, clinical identity. But a new name cannot repair a broken chart, eliminate study risk or resolve financing concerns. As one source put it bluntly, the sell-off reflects a market that no longer rewards sector hype.

Cybin (Helus Pharma) at a turning point? This analysis reveals what investors need to know now.

The bull case for Helus is more nuanced than a generic revival of psychedelic investing. The company has a late-stage programme, a second clinical asset with positive data, a recruitment-focused partnership, and political support that reduces friction. But the burden of proof is still high. An interim CEO structure ahead of a pivotal milestone is far from ideal, and political enthusiasm will not shield shareholders if the clinical results disappoint.

Helus Pharma has moved from story mode into execution mode. The real test begins when the APPROACH data lands in Q4 2026. Until then, the stock remains a bet on delivery — with no margin for error.

Ad

Cybin (Helus Pharma) Stock: New Analysis - 9 June

Fresh Cybin (Helus Pharma) information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Cybin (Helus Pharma) analysis...

en | CA23256X1006 | HELUS | boerse | 69509566 |